Analysed DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) News Sources
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
10-02-2026
yahoo.com
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
04-08-2026
yahoo.com
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
19-05-2026
yahoo.com
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
29-05-2026
yahoo.com
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
01-06-2026
yahoo.com
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
03-06-2026
yahoo.com
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
17-06-2026
yahoo.com
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
08-07-2026
yahoo.com
What is the current price of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The current price of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is $0.3573.
DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) since the previous trading day is $0.0129.
DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) since the previous trading day is 3.7456%.
What is the most recent average sentiment score for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The most recent average sentiment score for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is 69 out of 100.
What is the most recent average sentiment for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)?
The most recent sentiment for DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS) is .
SEC-8K** Filing Available For DEFENCE THERAPEUTICS INC (DTCFF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.